Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 in moderate to severe ulcerative colitis
NCT03760003Phase 2Completed
- Sponsor
- Abivax
- Start
- Aug 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of obefazimod in ulcerative colitis (UC) (4 arms), sponsored by Abivax. Primary endpoint: Modified Mayo Score Reduction from Baseline at 8 weeks. Started Aug 2019; status: completed.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03760003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760003.